EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Serina Therapeutics's enterprise value is $57.50 Mil.
Serina Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.62 Mil. Therefore, Serina Therapeutics's EV-to-EBITDA for today is -8.68.
The historical rank and industry rank for Serina Therapeutics's EV-to-EBITDA or its related term are showing as below:
SER'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.33 Med: 0 Max: 90.95
Current: -8.68
During the past 2 years, the highest EV-to-EBITDA of Serina Therapeutics was 90.95. The lowest was -14.33. And the median was 0.00.
SER's EV-to-EBITDA is ranked worse than 100% of 447
companies
in the Biotechnology industry
Industry Median: 9.29
vs SER: -8.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Serina Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Serina Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Serina Therapeutics EV-to-EBITDA Chart
Serina Therapeutics Annual Data
Trend
Dec21
Dec22
EV-to-EBITDA
-
-
Serina Therapeutics Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Mar24
EV-to-EBITDA
-
-
-
-
-
Competitive Comparison of Serina Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Serina Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Serina Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Serina Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Serina Therapeutics's EV-to-EBITDA falls into.
Serina Therapeutics's current Enterprise Value is $57.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Serina Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Serina Therapeutics's PE Ratio (TTM) for today is calculated as:
Serina Therapeutics's share price for today is $4.76.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Serina Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.337.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Serina Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SER has been successfully added to your